HWKN

HAWKINS INC. - 10-Q Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended September 30, 2007, and the six-month period ended on the same date. Hawkins, Inc. is a Minnesota-based company operating in three reportable segments: Industrial, Water Treatment, and Pharmaceutical. The company manufactures and distributes chemical products, including bulk chemicals like caustic soda, antimicrobial products, and pharmaceutical ingredients.

Key Financial Metrics

Note: The company reported no long-term debt on the balance sheet as of September 30, 2007. Current liabilities totaled $24,094,396, primarily consisting of accounts payable and accrued payroll.

Material Changes vs. Prior Period

• Revenue Growth: Sales increased 14.1% ($5.9M) for the quarter and 15.7% ($13.1M) for the six months compared to the prior year. This growth was driven by the acquisition of Trumark, Inc. (completed May 31, 2007) and volume increases in the Industrial and Water Treatment segments.
• Margin Compression: Gross margin percentage declined to 24.7% (quarter) and 24.5% (six months) from 26.5% and 26.3% in the prior year. This was attributed to a shift toward higher-volume, lower-margin products and rising material costs (specifically caustic soda) which were not fully offset by price increases.
• Operating Expenses: Selling, general, and administrative (SG&A) expenses increased significantly, partly due to costs associated with implementing a new Enterprise Resource Planning (ERP) system and non-recurring expenses related to the Trumark acquisition.
• Pharmaceutical Segment: Sales in this segment decreased 7.8% for the quarter due to ongoing restrictions by the FDA on certain products. However, the company received clearance to sell the majority of affected products shortly after the period end.

Outlook, Risks, and Management Commentary

• Acquisition Impact: The Trumark acquisition added approximately $6 million in purchase price (cash and stock) and is expected to contribute to future sales growth in the Industrial segment.
• ERP Implementation: The company is incurring significant costs for an ERP system upgrade, with consulting fees of approximately $1 million for the six-month period. These costs are expected to continue in fiscal 2008 before decreasing in 2009.
• FDA Restrictions: While the Pharmaceutical segment faced sales restrictions due to FDA validation issues regarding packaging and expiration dating, management noted the impact was not material to overall results. Clearance was received for most products post-period.
• Liquidity: The company maintains a strong liquidity position with $13.7 million in cash and $10.5 million in available-for-sale investments. Management does not anticipate the need for significant external financing.
• Market Risks: The company is exposed to commodity price fluctuations (e.g., caustic soda) and interest rate risks regarding its fixed-income investment portfolio. It does not currently use hedging instruments for commodity purchases.

Investor Verification Checklist

• Trumark Integration: Verify the full financial contribution of the Trumark acquisition in subsequent quarters to ensure projected synergies are realized.
• ERP Cost Trajectory: Monitor SG&A expenses to confirm that ERP implementation costs peak and decline as projected in fiscal 2009.
• FDA Resolution: Confirm that the Pharmaceutical segment sales have fully recovered following the FDA clearance received after September 30, 2007.
• Commodity Pricing: Track the company's ability to pass on rising raw material costs (specifically caustic soda) to customers to protect gross margins.
• Inventory Valuation: Review the LIFO reserve and inventory levels, as the company holds significant inventory valued under the LIFO method, which can cause margin volatility.